Entecavir Accord

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Entecavir

Available from:

Accord Healthcare S.L.U.

ATC code:

J05AF10

INN (International Name):

entecavir

Therapeutic group:

Antivirusi za sistemsko uporabo

Therapeutic area:

Hepatitis B, Kronični

Therapeutic indications:

Entecavir Accord is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with: , compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis. , decompensated bolezen jeter. Tako za odškodnino in decompensated bolezni jeter, ta navedba temelji na kliničnem preskušanju podatkov v nucleoside naivnih bolnikov z HBeAg pozitivnih in HBeAg negativnih HBV okužbe. Glede bolnikov z lamivudinom neodzivnega hepatitisa B. Entecavir Soglasju navede tudi za zdravljenje kronične HBV okužbe v nucleoside naivno pediatričnih bolnikih od 2 do.

Product summary:

Revision: 5

Authorization status:

Pooblaščeni

Authorization date:

2017-09-25

Patient Information leaflet

                                28
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Accord Healthcare S.L.U.
World Trade Center, Moll de Barcelona, s/n,
Edifici Est 6ª planta,
08039 Barcelona,
Španija
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
Pakiranje v plastenki:
EU/1/17/1211/001
30 filmsko obloženih tablet
Pakiranje v pretisnem omotu:
EU/1/17/1211/002
30 x 1 filmsko obložena tableta
EU/1/17/1211/003
90 x 1 filmsko obložena tableta
13.
ŠTEVILKA SERIJE
Številka serije
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Entecavir Accord 0,5 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – ČLOVEKU BERLJIVI PODATKOVNI ELEMENTI
PC
SN
NN
29
PODATKI NA PRIMARNI OVOJNINI
BESEDILO NA NALEPKI PLASTENKE
1.
IME ZDRAVILA
Entecavir Accord 0,5 mg filmsko obložene tablete
entekavir
2.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN
Ena tableta vsebuje 0,5 mg entekavirja v obliki entekavir monohidrata.
3.
SEZNAM POMOŽNIH SNOVI
Vsebuje tudi sojine polisaharide. Za dodatne informacije glejte
navodila za uporabo.
4.
FARMACEVTSKA OBLIKA IN VSEBINA
filmsko obložena tableta
30 filmsko obloženih tablet
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
peroralna uporaba
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
Uporabno do
Po odprtju plastenke porabiti v roku 90 dni.
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
30
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Accord
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/17/1211/001
13.
ŠTEVILKA SERIJE
Številka serije
14.
NAČIN IZDAJ
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Entecavir Accord 0,5 mg filmsko obložene tablete
Entecavir Accord 1 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Entecavir Accord 0,5 mg filmsko obložene tablete
Ena tableta vsebuje 0,5 mg entekavirja v obliki entekavir monohidrata.
Entecavir Accord 1 mg filmsko obložene tablete
Ena tableta vsebuje 1 mg entekavirja v obliki entekavir monohidrata.
Pomožne snovi z znanim učinkom
Ena 0,5 mg filmsko obložena tableta vsebuje 26 mg sojinih
polisaharidov.
Ena 1 mg filmsko obložena tableta vsebuje 52 mg sojinih
polisaharidov.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
filmsko obložena tableta (tableta)
Entecavir Accord 0,5 mg filmsko obložene tablete
Filmsko obložene tablete so bele do umazano bele barve, bikonveksne
in trikotne oblike. Na eni strani
imajo vtisnjeno oznako “J”, na drugi strani pa “110”.
Dimenzije: dolžina 8,70 mm ± 0,20 mm, širina 8,40 mm ± 0,20 mm in
debelina 3,40 mm ± 0,30 mm.
Entecavir Accord 1 mg filmsko obložene tablete
Filmsko obložene tablete so rožnate barve, bikonveksne in trikotne
oblike. Na eni strani imajo
vtisnjeno oznako “J”, na drugi strani pa “111”.
Dimenzije: dolžina 11,00 mm ± 0,20 mm, širina 10,60 mm ± 0,20 mm
in debelina 4,20 mm ±
0,30 mm.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Entecavir Accord je indicirano za zdravljenje kronične
okužbe z virusom hepatitisa B (HBV)
(glejte poglavje 5.1) pri odraslih:
•
s kompenzirano boleznijo jeter in dokazano aktivno replikacijo virusa,
persistentno
povečanimi vrednostmi serumske alanin-aminotransferaze (ALT) in
histološko dokazanim
aktivnim vnetjem in/ali fibrozo.
•
z dekompenzirano boleznijo jeter (glejte poglavje 4.4).
Pri obeh, kompenzirani in dekompenzirani bolezni jeter, indikacija
temelji na podatkih kliničnega
preskušanja pri HBeAg pozitivnih in HBeAg negativnih bolnikih,
okuženih s HBV, ki se še niso
3
zdravili z nukleozidi. Glede bolnikov s hepati
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 29-07-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 29-07-2022
Public Assessment Report Public Assessment Report Bulgarian 26-01-2018
Patient Information leaflet Patient Information leaflet Spanish 29-07-2022
Public Assessment Report Public Assessment Report Spanish 26-01-2018
Patient Information leaflet Patient Information leaflet Czech 29-07-2022
Public Assessment Report Public Assessment Report Czech 26-01-2018
Patient Information leaflet Patient Information leaflet Danish 29-07-2022
Public Assessment Report Public Assessment Report Danish 26-01-2018
Patient Information leaflet Patient Information leaflet German 29-07-2022
Public Assessment Report Public Assessment Report German 26-01-2018
Patient Information leaflet Patient Information leaflet Estonian 29-07-2022
Public Assessment Report Public Assessment Report Estonian 26-01-2018
Patient Information leaflet Patient Information leaflet Greek 29-07-2022
Public Assessment Report Public Assessment Report Greek 26-01-2018
Patient Information leaflet Patient Information leaflet English 29-07-2022
Public Assessment Report Public Assessment Report English 26-01-2018
Patient Information leaflet Patient Information leaflet French 29-07-2022
Public Assessment Report Public Assessment Report French 26-01-2018
Patient Information leaflet Patient Information leaflet Italian 29-07-2022
Public Assessment Report Public Assessment Report Italian 26-01-2018
Patient Information leaflet Patient Information leaflet Latvian 29-07-2022
Public Assessment Report Public Assessment Report Latvian 26-01-2018
Patient Information leaflet Patient Information leaflet Lithuanian 29-07-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 29-07-2022
Public Assessment Report Public Assessment Report Lithuanian 26-01-2018
Patient Information leaflet Patient Information leaflet Hungarian 29-07-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 29-07-2022
Public Assessment Report Public Assessment Report Hungarian 26-01-2018
Patient Information leaflet Patient Information leaflet Maltese 29-07-2022
Public Assessment Report Public Assessment Report Maltese 26-01-2018
Patient Information leaflet Patient Information leaflet Dutch 29-07-2022
Public Assessment Report Public Assessment Report Dutch 26-01-2018
Patient Information leaflet Patient Information leaflet Polish 29-07-2022
Public Assessment Report Public Assessment Report Polish 26-01-2018
Patient Information leaflet Patient Information leaflet Portuguese 29-07-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 29-07-2022
Public Assessment Report Public Assessment Report Portuguese 26-01-2018
Patient Information leaflet Patient Information leaflet Romanian 29-07-2022
Public Assessment Report Public Assessment Report Romanian 26-01-2018
Patient Information leaflet Patient Information leaflet Slovak 29-07-2022
Public Assessment Report Public Assessment Report Slovak 26-01-2018
Patient Information leaflet Patient Information leaflet Finnish 29-07-2022
Public Assessment Report Public Assessment Report Finnish 26-01-2018
Patient Information leaflet Patient Information leaflet Swedish 29-07-2022
Public Assessment Report Public Assessment Report Swedish 26-01-2018
Patient Information leaflet Patient Information leaflet Norwegian 29-07-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 29-07-2022
Patient Information leaflet Patient Information leaflet Icelandic 29-07-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 29-07-2022
Patient Information leaflet Patient Information leaflet Croatian 29-07-2022
Public Assessment Report Public Assessment Report Croatian 26-01-2018

Search alerts related to this product